Burning Questions About New and Emerging Injectable Therapies for Type 2 Diabetes: A Hot Topics Presentation
To maintain glycemic control, most patients with T2DM will eventually require insulin and/or other injectable agents, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Newer, ultralong-acting basal insulins offer patients with T2DM the potential for greater regimen flexibility and possibility of less hypoglycemia risk compared with other basal analogues. Combination therapy using a GLP-1 RA and insulin has recently emerged as a favored treatment for many patients with T2DM due to its high efficacy, low risk of hypoglycemia, and low risk of weight gain. Cardiovascular outcomes trials have demonstrated neutral to beneficial effects of basal insulin and GLP-1 RAs on major adverse cardiovascular events, and these benefits have been seen in patients with and without comorbid cardiovascular and renal disease. However, the indications, benefits, and limitations of each of the available GLP-1 RAs vary. The recent approval of several coformulations of insulin and GLP-1 RAs has heightened the need for endocrinologists to be aware of the differences between injectable therapies so that they can engage in shared decision making with their patients, as advocated in current guidelines. Accordingly, participants in this activity will learn when, why, and how to use new and emerging injectable therapies for T2DM, including in patients with cardiovascular or renal disease.
Please Note: this course is housed on Medscape. Upon selecting 'Take Course,' you will be redirected to Medscape to compete the activity.
This activity was developed for endocrinologists and other endocrinology healthcare providers who treat patients with type 2 diabetes mellitus (T2DM).
Upon completion of this activity, participants will be able to:
- Evaluate the safety, efficacy, and dosing recommendations for long-acting vs ultralong-acting basal insulin analogues in patients with T2DM
- Describe anticipated clinical outcomes associated with using a basal insulin, a GLP-1 RA, or both in injection-naïve patients with T2DM
- Summarize available cardiovascular outcomes data for ultralong-acting insulins and GLP-1 RAs
- Compare and contrast clinical outcomes in patients with and without renal impairment treated with ultralong-acting insulins or GLP-1 RAs
The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 AMA
- 1.75 Attendance